654 results on '"Drummond, Michael"'
Search Results
2. Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement
3. Colonoscopy vs the Fecal Immunochemical Test: Which is Best?
4. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
5. Estimation of Societal Values of Health States Preferences at the National Level for Low- and Middle-Income Countries
6. Transparency, openness, and reproducible research practices are frequently underused in health economic evaluations
7. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration
8. GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations
9. Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments
10. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures
11. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
12. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
13. Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report
14. Consideration of quality of life in the health technology assessments of rare disease treatments
15. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
16. Ancient Secretory Pathways Contributed to the Evolutionary Origin of an Ecologically Impactful Bioluminescence System.
17. Promoting innovation while controlling cost: The UK's approach to health technology assessment
18. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
19. Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe
20. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective
21. Should health technology assessment be more patient centric? If so, how?
22. Economic evaluation of nutrition interventions: Does one size fit all?
23. LSE–Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19
24. A Value Framework for the Assessment of Diagnostic Technologies: A Proposal Based on a Targeted Systematic Review and a Multistakeholder Deliberative Process in Latin America
25. Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review.
26. Challenges with coverage with evidence development schemes for medical devices: A systematic review
27. Is rate of return pricing a useful approach when value-based pricing is not appropriate?
28. An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
29. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis
30. Patient Preferences in the Medical Product Lifecycle
31. Disparities in access to food and chronic obstructive pulmonary disease (COPD)-related outcomes: a cross-sectional analysis
32. Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
33. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America
34. Brief Report: HIV Is Associated With Impaired Pulmonary Diffusing Capacity Independent of Emphysema
35. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
36. Does the approach to economic evaluation in health care depend on culture, values, and institutional context?
37. Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]
38. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]
39. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]
40. An Evaluation of Swedish Health Economics Research
41. Common Methodological Flaws in Economic Evaluations
42. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project
43. The Lag between Effectiveness and Cost-Effectiveness Evidence of New Drugs: Implications for Decision-Making in Health Care
44. ISPOR Code of Ethics 2017 (4th Edition)
45. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward
46. Establishing a reasonable price for an orphan drug
47. Single cell transcriptomics of human epidermis identifies basal stem cell transition states
48. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches
49. Laboratory culture of the California Sea Firefly Vargula tsujii (Ostracoda: Cypridinidae): Developing a model system for the evolution of marine bioluminescence
50. Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.